The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1650
May 16, 2022
View Complete Issue         Table of Contents 2019 
Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy
May 16, 2022 (Issue: 1650)
The FDA has approved Tarpeyo (Calliditas), a delayed-release capsule formulation of the corticosteroid budesonide, to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN; also called Berger's disease) who are at risk of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy
Article code: 1650c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.